Receiving a favorable analyst rating has significantly boosted Lantheus Holdings, Inc. (NASDAQ: LNTH) shares yesterday. The stock saw a remarkable increase, closing the previous session 36.65% higher at $106.18. The previous session’s trajectory appears to be contributing to the LNTH stock’s relative stabilization today, as it was up at $121.89 with a little -1.40% decrease.
Analyst Rating and Price Target Increase
On Wednesday, the well-regarded analyst firm, JMP Securities, reaffirmed its Market Outperform rating for Lantheus (LNTH) stock. The firm also raised the 12-month price target from $100 to $130, reflecting increased confidence in the company’s prospects.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Proposed Rule by CMS and Its Effects
Following a major step, Lantheus announced its support for the Centers for Medicare & Medicaid Services’ (CMS) Proposed Medicare Hospital Outpatient Prospective Payment System (OPPS) Rule for the 2025 calendar year. This recommendation was favorable. The purpose of this regulation is to improve patient access for Medicare beneficiaries by increasing payment for specialty diagnostic radiopharmaceuticals.
Specifically, CMS suggested paying separately for any diagnostic radiopharmaceutical whose daily cost exceeded $630. Payment for nuclear medicine tests includes the cost of diagnostic radiopharmaceuticals under the current OPPS regulations.
Even when the typical pass-through payment status expires, the proposed rule permits new diagnostic radiopharmaceuticals, such as PYLARIFY, to continue receiving separate payments from CMS for standard Medicare Fee-for-Service patients in hospital outpatient settings.
Promoting Fair Access
In order to improve patient outcomes by assisting healthcare practitioners in identifying and staging illnesses, Lantheus advocates for fair access to sophisticated diagnostic radiopharmaceuticals.
PYLARIFY, a fluorinated small molecule PSMA-targeted PET imaging agent used to identify lymph nodes, bone, and soft tissue metastases in cases of recurring and/or metastatic prostate cancer, is one example of a diagnostic radiopharmaceutical whose significance is recognized by the proposed regulations.
Beginning in early November, the final regulation will be published and go into effect on January 1, 2025. As it continues to carry out all-encompassing tactics to preserve patient access to these vital diagnostic instruments, Lantheus is dedicated to working with coalition partners and supporters to get distinct funding solutions for 2025.
